HOME >> BIOLOGY >> NEWS
Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms

HORSHAM, PA (April 3, 2000) -- Exisulind (Aptosyn™) and other selective apoptotic antineoplastic drugs (SAANDs) inhibit the growth of prostate cancer cells in two ways, said researchers from Columbia University and their collaborators at Cell Pathways, Inc. (Nasdaq: CLPA). First, they directly kill cancerous prostate cells by inducing apoptosis. Secondly, they decrease expression of the androgen receptor in the cancerous prostate cells, making them less responsive to the growth-promoting effects of androgens in their environment. The Columbia University scientists and their Cell Pathways' collaborators presented their preclinical findings on Sunday April 2, 2000 at the annual meeting of the American Association for Cancer Research (AACR) in San Francisco.

The researchers also demonstrated in a prostate cancer cell line that exisulind (Aptosyn™) and two other SAANDs, CP461 and CP248, inhibited the cellular expression and secretion of prostate specific antigen (PSA) at the same concentrations that induced apoptosis in the cells.

Dr. Bernard Weinstein, the senior investigator of these studies and director of the Columbia University Comprehensive Cancer Center, emphasized that "because of their dual mechanism of action, these agents are also effective in prostate cancer cells that have become independent of androgens."

"These findings also support the usefulness of PSA assays for measuring the efficacy of SAANDs in clinical trials for prostate cancer therapy or chemoprevention, as they demonstrate that a reduction in PSA levels accurately reflects cell death and not merely a reduction in PSA production when these drugs are used," added Rifat Pamukcu, M.D., chief scientific officer and senior vice president of research at Cell Pathways, Inc.

"This laboratory research complements the findings of our clinical trial of exisulind (Aptosyn™) as a treatment for post-prostatectomy men at risk of prostate cancer recurre
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
2-Apr-2000


Page: 1 2 3

Related biology news :

1. New molecular link key to cellular proteins involved in cancer progression, other diseases
2. New hydrothermal vents discovered as South Pacific Odyssey research begins
3. Posters highlight water, energy and other natural resource research
4. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
5. K-State, other universities to study how climate affects plant evolution
6. The search for a kinder, gentler chemotherapy
7. Green tea research leads to gum and other products
8. New survey reveals insights into unique relationship between mothers and pediatricians
9. Manatee population rising in some regions, likely stalled or declining in others
10. Study shows impact of emotionally healthy fathers when mothers poor mental health affects children
11. Another key for the p53 door

Post Your Comments:
(Date:1/22/2015)... ROBERTS, Washington , January 20, 2015 ... and tech stocks, releases video from the CES 2015 (Consumer ... consultant Apollo Robbins . Apollo shows how ... biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 2
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
Cached News: